Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants

References

• Callaway E. Why does the Omicron sub-variant spread faster than the original? Nature. 2022;602(7898):556–557.
   PubMedGoogle Scholar
• Coronavirus disease (COVID-19): weekly epidemiological update. 2022. Available from: https://reliefweb.int/report/world/coronavirus-disease-covid-19-weekly-epidemiological-update-29-june-2022.
   Google Scholar
• Control CfD, Prevention. Centers for disease control and prevention COVID data tracker: vaccination demographics trends. 2021.
   Google Scholar
• Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021 Jul 14;29(7):1124–1136.e11.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature. 2022;608(7923):593–602.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422–2433.e13.
   PubMed Web of Science ®Google Scholar
• Afkhami S, D'Agostino MR, Zhang A, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185(5):896–915.e19.
   PubMed Web of Science ®Google Scholar
• Langel SN, Johnson S, Martinez CI, et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med. 2022;14(658):eabn6868.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081.
   PubMed Web of Science ®Google Scholar
• Heida R, Hinrichs WL, Frijlink HW. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Rev Vaccines. 2022 Jul;21(7):957–974.
   PubMed Web of Science ®Google Scholar
• Li J-X, Wu S-P, Guo X-L, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–748.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
   PubMed Web of Science ®Google Scholar
• Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc Natl Acad Sci USA. 2021;118(36):e2103154118.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao Z, Cui T, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg Microbes Infect. 2022 Dec;11(1):829–840.
   PubMed Web of Science ®Google Scholar
• Chen Q, Nie J, Huang W, et al. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. Hum Vaccin Immunother. 2018 Jan 2;14(1):199–208.
   PubMed Web of Science ®Google Scholar
• Cheng ZJ, Huang H, Zheng P, et al. Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization. Allergy. 2022 Mar 7;77(8):2404–2414.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang X, Mei X, et al. SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies. Signal Transduct Target Ther. 2022;7(1):132.
   PubMed Web of Science ®Google Scholar
• CDC COVID data tracker: variant proportions. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
   Google Scholar
• Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol. 2004;74(2):328–335.
   PubMed Web of Science ®Google Scholar
• Doremalen N, Purushotham JN, Schulz JE, et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021;13(607):eabh0755.
   PubMed Web of Science ®Google Scholar
• Feng L, Wang Q, Shan C, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020;11(1):4207.
   PubMed Web of Science ®Google Scholar